guest ::
| Home > Publications Database > Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. > print |
| Home > Publications Database > Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. > print |
| 001 | 165605 | ||
| 005 | 20240222115046.0 | ||
| 024 | 7 | _ | |a pmc:PMC9715912 |2 pmc |
| 024 | 7 | _ | |a 10.1016/j.celrep.2022.111698 |2 doi |
| 024 | 7 | _ | |a pmid:36417883 |2 pmid |
| 024 | 7 | _ | |a 2211-1247 |2 ISSN |
| 024 | 7 | _ | |a 2639-1856 |2 ISSN |
| 024 | 7 | _ | |a altmetric:138761387 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-01738 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bakker, Wineke |b 0 |
| 245 | _ | _ | |a Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. |
| 260 | _ | _ | |a [New York, NY] |c 2022 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1708514151_22067 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Therapies based on glucagon-like peptide-1 (GLP-1) long-acting analogs and insulin are often used in the treatment of metabolic diseases. Both insulin and GLP-1 receptors are expressed in metabolically relevant brain regions, suggesting a cooperative action. However, the mechanisms underlying the synergistic actions of insulin and GLP-1R agonists remain elusive. In this study, we show that insulin-induced hypoglycemia enhances GLP-1R agonists entry in hypothalamic and area, leading to enhanced whole-body fat oxidation. Mechanistically, this phenomenon relies on the release of tanycyctic vascular endothelial growth factor A, which is selectively impaired after calorie-rich diet exposure. In humans, low blood glucose also correlates with enhanced blood-to-brain passage of insulin, suggesting that blood glucose gates the passage other energy-related signals in the brain. This study implies that the preventing hyperglycemia is important to harnessing the full benefit of GLP-1R agonist entry in the brain and action onto lipid mobilization and body weight loss. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a CP: Metabolism |2 Other |
| 650 | _ | 7 | |a brain access |2 Other |
| 650 | _ | 7 | |a diabetes |2 Other |
| 650 | _ | 7 | |a glucagon-like peptide 1 analogs |2 Other |
| 650 | _ | 7 | |a glycemic control |2 Other |
| 650 | _ | 7 | |a metabolism |2 Other |
| 650 | _ | 7 | |a nutrient partitioning |2 Other |
| 650 | _ | 7 | |a obesity |2 Other |
| 650 | _ | 7 | |a tanycyte |2 Other |
| 650 | _ | 7 | |a Blood Glucose |2 NLM Chemicals |
| 650 | _ | 7 | |a Vascular Endothelial Growth Factor A |2 NLM Chemicals |
| 650 | _ | 7 | |a Glucagon-Like Peptide 1 |0 89750-14-1 |2 NLM Chemicals |
| 650 | _ | 7 | |a Insulin |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Blood Glucose: metabolism |2 MeSH |
| 650 | _ | 2 | |a Vascular Endothelial Growth Factor A: metabolism |2 MeSH |
| 650 | _ | 2 | |a Glucagon-Like Peptide 1: metabolism |2 MeSH |
| 650 | _ | 2 | |a Insulin: metabolism |2 MeSH |
| 650 | _ | 2 | |a Homeostasis |2 MeSH |
| 650 | _ | 2 | |a Brain: metabolism |2 MeSH |
| 700 | 1 | _ | |a Imbernon, Monica |b 1 |
| 700 | 1 | _ | |a Salinas, Casper Gravesen |b 2 |
| 700 | 1 | _ | |a Moro Chao, Daniela Herrera |b 3 |
| 700 | 1 | _ | |a Hassouna, Rim |b 4 |
| 700 | 1 | _ | |a Morel, Chloe |b 5 |
| 700 | 1 | _ | |a Martin, Claire |b 6 |
| 700 | 1 | _ | |a Leger, Caroline |b 7 |
| 700 | 1 | _ | |a Denis, Raphael G P |b 8 |
| 700 | 1 | _ | |a Castel, Julien |b 9 |
| 700 | 1 | _ | |a Peter, Andreas |b 10 |
| 700 | 1 | _ | |a Heni, Martin |b 11 |
| 700 | 1 | _ | |a Maetzler, Walter |0 P:(DE-2719)2810915 |b 12 |u dzne |
| 700 | 1 | _ | |a Nielsen, Heidi Solvang |b 13 |
| 700 | 1 | _ | |a Duquenne, Manon |b 14 |
| 700 | 1 | _ | |a Schwaninger, Markus |b 15 |
| 700 | 1 | _ | |a Lundh, Sofia |b 16 |
| 700 | 1 | _ | |a Johan Hogendorf, Wouter Frederic |b 17 |
| 700 | 1 | _ | |a Gangarossa, Giuseppe |b 18 |
| 700 | 1 | _ | |a Secher, Anna |b 19 |
| 700 | 1 | _ | |a Hecksher-Sørensen, Jacob |b 20 |
| 700 | 1 | _ | |a Pedersen, Thomas Åskov |b 21 |
| 700 | 1 | _ | |a Prevot, Vincent |b 22 |
| 700 | 1 | _ | |a Luquet, Serge |b 23 |
| 773 | _ | _ | |a 10.1016/j.celrep.2022.111698 |g Vol. 41, no. 8, p. 111698 - |0 PERI:(DE-600)2649101-1 |n 8 |p 111698 |t Cell reports |v 41 |y 2022 |x 2211-1247 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/165605/files/DZNE-2022-01738.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/165605/files/DZNE-2022-01738.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:165605 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2810915 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-03 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CELL REP : 2021 |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-01-26T13:08:57Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-01-26T13:08:57Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-17 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2021-01-26T13:08:57Z |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-02-03 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CELL REP : 2021 |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-02-03 |
| 920 | 1 | _ | |0 I:(DE-2719)5000024 |k AG Maetzler |l Functional Neurogeriatrics |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000024 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|